Pulmonx Corporation (NASDAQ:LUNG) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Pulmonx Corporation has received an average consensus recommendation of "Moderate Buy" from nine analysts, with four recommending a hold and five a buy.
• The company's stock price objective has significantly varied, with estimates ranging from $3.00 to $16.00 among different analysts.
• Pulmonx reported a loss of ($0.38) earnings per share for the last quarter, slightly exceeding the consensus estimate, along with revenues of $23.86 million.

Shares of Pulmonx Corporation (NASDAQ:LUNG - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the nine ratings firms that are covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $7.6643.

Several brokerages have weighed in on LUNG. Lake Street Capital dropped their target price on Pulmonx from $12.00 to $8.00 and set a "buy" rating on the stock in a research report on Thursday, July 31st. Stifel Nicolaus dropped their price objective on shares of Pulmonx from $16.00 to $5.00 and set a "buy" rating on the stock in a report on Thursday, July 31st. Wells Fargo & Company reduced their target price on shares of Pulmonx from $6.00 to $3.00 and set an "equal weight" rating for the company in a research note on Friday, August 1st. Wall Street Zen upgraded Pulmonx from a "sell" rating to a "hold" rating in a research report on Saturday, August 30th. Finally, D. Boral Capital restated a "buy" rating and issued a $16.00 target price on shares of Pulmonx in a research report on Monday, September 8th.

Pulmonx Stock Performance

LUNG stock traded up $0.15 during trading on Friday, hitting $1.84. 585,855 shares of the company's stock traded hands, compared to its average volume of 443,003. The stock has a market capitalization of $74.98 million, a price-to-earnings ratio of -1.29 and a beta of 0.43. Pulmonx has a 52 week low of $1.47 and a 52 week high of $9.37. The stock has a fifty day moving average price of $2.02 and a two-hundred day moving average price of $3.57. The company has a quick ratio of 4.63, a current ratio of 5.35 and a debt-to-equity ratio of 0.54.

Pulmonx (NASDAQ:LUNG - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.40) by $0.02. Pulmonx had a negative net margin of 62.88% and a negative return on equity of 69.76%. The business had revenue of $23.86 million during the quarter, compared to the consensus estimate of $23.46 million. Pulmonx has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Pulmonx will post -1.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Pulmonx

Several large investors have recently made changes to their positions in the business. Rhumbline Advisers grew its stake in shares of Pulmonx by 4.6% in the 1st quarter. Rhumbline Advisers now owns 55,958 shares of the company's stock valued at $377,000 after buying an additional 2,455 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Pulmonx by 1.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 320,946 shares of the company's stock worth $2,160,000 after acquiring an additional 5,414 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of Pulmonx in the 4th quarter valued at $43,000. Northern Trust Corp increased its position in Pulmonx by 2.9% during the fourth quarter. Northern Trust Corp now owns 372,659 shares of the company's stock worth $2,530,000 after buying an additional 10,433 shares during the last quarter. Finally, ProShare Advisors LLC acquired a new stake in shares of Pulmonx in the fourth quarter worth about $72,000. Institutional investors own 91.04% of the company's stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.